Tris Pharma Hires President for Generic Pharmaceuticals Business
MONMOUTH JUNCTION, N.J., June 20, 2013 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that it has named Janet Penner as President of its new generic pharmaceuticals business.
Tris' generic pharmaceuticals business, with its own distinct sales, marketing and distribution, will be responsible for commercializing Tris' Abbreviated New Drug Applications (ANDAs) while leveraging Tris' considerable manufacturing capabilities. Tris currently has 13 FDA-approved ANDA products, including several 'first-to-market' generics. All of Tris' generic products are manufactured in its FDA-inspected, state-of-the art 130,000-square-foot facility in New Jersey.
"Tris' generics initiative is a natural evolution of the overall strategic vision at Tris; bringing technologically-challenging, high-quality products to the marketplace," said Ketan Mehta, President and CEO of Tris Pharma.
Janet comes to Tris with a wealth of expertise in the commercialization of generic products. She brings nearly 15 years of experience in leadership roles within the generic pharmaceuticals industry, including AmerisourceBergen, where she was responsible for the purchasing of generic pharmaceuticals. Most recently, Janet headed sales & marketing at CorePharma. Janet has also held various positions of growing responsibility at General Electric and PepsiCo, and holds an MBA.
"Tris' unique technology for liquid sustained-release products, along with the continued expansion of its strategic pipeline of both liquid and solid oral dosage ANDA development projects, has me truly excited to spearhead the generic pharmaceuticals business at Tris," said Ms. Penner.
About Tris Pharma
Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies-driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, U.S.A. For more information, please visit http://www.trispharma.com.
SOURCE Tris Pharma